Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
ConclusionsThe efficacy of baricitinib 4 mg in Chinese patients with moderately to severely active RA and prior MTX-IR was clinically significant compared to placebo regardless of baseline characteristics. Baricitinib was well tolerated with an acceptable safety profile during the full study period.Trial RegistrationNCT02265705
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Arthritis | China Health | Disability | Methotrexate | Pain | Rheumatoid Arthritis | Rheumatology | Statistics | Study